A Study to Evaluate the Pharmacodynamic Activity of E2730 in Adult Participants With Photosensitive Epilepsy

Summary

The primary purpose of the study is to assess the pharmacodynamic (PD) activity of E2730 as measured by suppression of epileptic photoparoxysmal response (PPR) in the participant's most sensitive eye condition in participants with photosensitive epilepsy.

Timeline

Start

2018-07-27

Primary completion

2019-02-14

Completion

2019-02-14

Outcome

Missed primary endpoint

Stopped: “The study was stopped due to efficacy reasons.”

registry analysis (superiority test); Treatment A: Placebo vs Treatment B: E2730 40 mg; LS Mean difference 1.38 (90% CI -0.72 to 3.48) NCT03603639 ↗

registry analysis (superiority test); Treatment A: Placebo vs Treatment C: E2730 120 mg; LS Mean difference 1.07 (90% CI -0.49 to 2.63) NCT03603639 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	E2730	Unknown	40 mg	Oral
Subject	E2730	Unknown	120 mg	Oral

Indications